CON/217/RX4 = Supply of COBALT Drug Trial Requirements

Tender description

<p>Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust are seeking expressions of interest from capable bidders for the following opportunity - COmBining memantine And cholinesterase inhibitors in Lewy body dementia treatment Trial (COBALT).<br /><br />Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust (CNTW) and The University of Melbourne (UoM), Australia have successfully bid for funding to run 2 National, multi-site, placebo controlled clinical trial assessing if adjunctive Memantine use in patients with Lewy Body Dementia (LBD) and Parkinson&rsquo;s Disease Dementia (PDD) has any effect on Clinical Global Impression (CGI) after 6 or 12 months. One trial will be based in the UK and sponsored by CNTW NHS FT and the second trial will be sponsored and run in Australia by The University of Melbourne (UoM). Both trials will run at the same time, use the same protocol, trial management and Investigational Medicinal Product (IMP). The trial will require active treatment with Memantine 5mg and 10mg tablets for a period of 12 months and the manufacture of a matching placebo 5mg and 10mg tablets. The trial will be run in the UK by the Dementia Research Team at Newcastle Biomedical Research Centre and sponsored by CNTW NHS FT.</p> <p>Full details of the opportunity can be found in the tender documents. To access these documents please 'express an interest' via the link available on this page.</p> Keywords: memantine and cholinesterase inhibitors in Lewy body dementia treatment trial, Parkinson’s Disease Dementia (PDD) has any effect on Clinical Global Impression (CGI), multi-site, placebo controlled clinical trial assessing if adjunctive Memantine use in patients